By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) — Ohio State University and Indiana University will use a $9 million award from the National Cancer Institute to continue studies on cancer genes and the epigenetic agents that mask their expression.

Over the next five years, researchers from both universities will study epigenetic changes in prostate, breast, and ovarian cancer cells that cause resistance to hormonal therapy or traditional chemotherapy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.

The New York Times editorial board weighs in on scientific research misconduct.

The European Commission says it won't take funds from the European Research Council's budget for its new European Fund for Strategic Investment.

The case of the 'devious defecator' examines the protections of the Genetic Information Nondiscrimination Act.